Halozyme Therapeutics, Inc. (HALO) Stock Analysis 2026
BriMind AI Score
ProprietaryScore based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.
BriMind 1-Year Price Target
An even blend of the BriMind AI model's DCF and momentum target ($168.77) and Wall Street's consensus target ($108.78).
AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →
HALO Revenue & Profitability Breakdown
This chart shows how HALO's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.
Key Financial Metrics
Halozyme Therapeutics, Inc. trades at a trailing P/E of 31.95x, generates $337.3M in free cash flow, runs a debt/equity ratio of 1517.69, and converts shareholder equity into profit at a 173.7% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.
Wall Street Analyst Consensus
Wall Street analysts covering Halozyme Therapeutics, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $99.56 (-24.1% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.
Intrinsic Value Estimates for HALO
We use 3 valuation models to estimate HALO's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.
Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.
Technical Price Signals
HALO is currently in a golden cross pattern, trading above its 50-day average of $88.32 and above its 200-day average of $73.62. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.
Compare HALO with Peers
Further Reading
Research and guides that put HALO’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.
More Healthcare Stock Analysis
In-depth reports on companies operating alongside HALO — business models, bull and bear cases, and the metrics that matter.
Unlock the Full HALO Analysis
Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.